Ruiping XIAO
Email: xiaor(at)pku(dot)edu(dot)cn;
Telephone: +86-10-62757243;
Lab Homepage: http://www.imm.pku.edu.cn/news.php?id=29
Research Area:
Dr. Xiao has made important discoveries in beta-adrenergic receptor (AR) subtype signaling, with an emphasis on translating bench discoveries to the bedside. She was the first to show thatbeta2-AR dually couples to Gs and Gi, revealing a new signaling paradigm of the G protein-coupled receptor superfamily. While chronic beta1-AR stimulation causes heart cell death and cardiomyopathy by Ca2+/calmodulin kinase II-dependent pathways, beta2-AR is cardiac protective. She co-invented the Gs-biased, chiral beta2-AR agonist R,R-feneterol and co-supervised its Phase I clinical trial (Phase II planned), spearheading a novel therapy treating heart failure with beta2-AR agonist R,R-feneterol or derivatives combined with beta1-AR blocker. Her current research has revealed that MG53 E3 ligase-mediated, ubiquitin-dependent degradation of insulin receptor and insulin receptor substrate 1 constitutes a fundamental mechanism for the development of systemic insulin resistance, leading to the sequelae of metabolic syndrome and cardiovascular complications. She has authored >140 peer-reviewed publications. She has been global leader in biomedical research and served as the founding director of the Institute of Molecular Medicine, Peking University since 2005. She has also played a leadership role in clinical translational research and currently serves as an Associate Editor of The New England Journal of Medicine。
Selected Publications: